Boron agents termed GluBs, developed by Science Tokyo researchers, have overcome a key limitation in cancer therapy by entering tumor cells through a pathway that standard drugs cannot use. The GluBs target ASCT2, a transporter abundant in aggressive cancers such as glioblastoma and breast cancer, rather than the LAT1 route. Results from cell and animal studies show the agents were safe and effective in limiting tumor growth, indicating the potential to treat cancers with limited LAT1 expression.
This article was originally published on MedicalXpress.com
